Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03567590
Other study ID # KY 2018-027-02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 5, 2018
Est. completion date January 5, 2021

Study information

Verified date October 2021
Source Beijing Tiantan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators aim to investigate the effectiveness and safety of sphenopalatine ganglion pulsed radiofrequency on cluster headache.


Description:

The investigators aim to investigate whether the sphenopalatine ganglion pulsed radiofrequency treatment is better than traditional sphenopalatine ganglion nerve block technology and provides medical evidence for the clinical application and promotion of sphenopalatine ganglion pulsed radiofrequency treatment to provide a minimally invasive, safe, and effective treatment for patients with cluster headache who do not respond to drug treatment.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date January 5, 2021
Est. primary completion date April 24, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - diagnosis of cluster headache is confirmed according to the diagnostic criteria of the 2018 International Classification of Headache Disorders 3rd edition (ICHD-3); - patient's age is between 18 and 60 years; - patients seek treatment in the pain clinics of hospitals participating in the study within 5 days of the onset of the cluster period; pain conditions of patients remain the same after conservative treatment of conventional oral medication, or the reduction rates are less than 50% in pain degree during headache attacks, headache attack frequency, duration of each headache attack, and auxiliary analgesic drug dosage; and - patients signed the informed consent. Exclusion Criteria: - abnormalities in blood measurements, liver and kidney function, blood glucose, coagulation, electrocardiogram, and chest radiograph; - infection at the puncture site; - previous mental illness; - previous history of narcotic drug abuse; - history of anticoagulant and antiplatelet aggregation drugs; - implantable pulse generator; - previous history of invasive treatments such as sphenopalatine ganglion radiofrequency thermocoagulation and chemical destruction; - pregnant or breastfeeding patients.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Pulsed Radiofrequency treatment
The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.
Nerve Block treatment
A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.

Locations

Country Name City State
China Beijing Sanbo Brain Hospital Beijing Beijing
China Beijing Tiantan Hospital Beijing Beijing
China Jilin Province People's Hospital Changchun Jilin

Sponsors (3)

Lead Sponsor Collaborator
Beijing Tiantan Hospital Beijing Sanbo Brain Hospital, Jilin Province People's Hospital

Country where clinical trial is conducted

China, 

References & Publications (6)

Barloese MC, Jürgens TP, May A, Lainez JM, Schoenen J, Gaul C, Goodman AM, Caparso A, Jensen RH. Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months. J Headache Pain. 2016 Dec;17(1):67. doi: 10.1186/s10194-016-0658-1. Epub 2016 Jul 26. — View Citation

Kohlmeier C, Behrens P, Böger A, Ramachandran B, Caparso A, Schulze D, Stude P, Heiland M, Assaf AT. Improved surgical procedure using intraoperative navigation for the implantation of the SPG microstimulator in patients with chronic cluster headache. Int J Comput Assist Radiol Surg. 2017 Dec;12(12):2119-2128. doi: 10.1007/s11548-016-1512-2. Epub 2017 Jan 12. — View Citation

Lepper A, Frese A, Summ O, Nofer JR, Evers S. Hypothalamic dopaminergic stimulation in cluster headache. Cephalalgia. 2013 Oct;33(14):1155-9. doi: 10.1177/0333102413487445. Epub 2013 Apr 29. — View Citation

Loomba V, Upadhyay A, Kaveeshvar H. Radiofrequency Ablation of the Sphenopalatine Ganglion Using Cone Beam Computed Tomography for Intractable Cluster Headache. Pain Physician. 2016 Sep-Oct;19(7):E1093-6. — View Citation

Peñarrocha-Diago M, Boronat A, Peñarrocha-Oltra D, Ata-Ali J, Bagan JV, Peñarrocha-Diago M. Clinical course of patients with episodic cluster headache treated with corticosteroids inproximity to the sphenopalatine ganglion: a preliminary study of 23 patients. Med Oral Patol Oral Cir Bucal. 2012 May 1;17(3):e477-82. — View Citation

Weaver-Agostoni J. Cluster headache. Am Fam Physician. 2013 Jul 15;88(2):122-8. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of the cluster period The duration of the cluster period is defined as the total duration of the headache, including the pain attack time before and after treatment. Within 1 year (the cluster period is not over 3 months generally)
Secondary The degree of pain during headache attacks after treatment Evaluated by numeric rating scale (NRS, 0 points for no pain and 10 points for the most severe pain) 1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery
Secondary Headache attack frequency The number of attacks per day 1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery
Secondary Duration of each headache attack Duration of each headache attack after treatment 1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery
Secondary Dose of auxiliary analgesic drugs Dose of auxiliary analgesic drugs per day 1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery
Secondary Duration of remission period From the end of this cluster period to the beginning of the next cluster period 1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery
Secondary Patient satisfaction Patient satisfactory scale (PSS) evaluation (0 for unsatisfactory, and 10 for very satisfied). 1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery
Secondary Effective rate The effectiveness rate is calculated as follows: effectiveness rate = the number of effective patients / total number of patients in this group × 100%. 1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05264714 - Cluster Headache Treatment With Rimegepant Phase 2
Completed NCT01677026 - Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Terminated NCT00203190 - A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache Phase 4
Terminated NCT04570475 - High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache Phase 3
Completed NCT04066023 - Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches Phase 2/Phase 3
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT02019017 - Botox Injection in Treatment of Cluster Headache Phase 1/Phase 2
Completed NCT05153876 - An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
Recruiting NCT05324748 - Repeated GON Injections in CCH Phase 3
Completed NCT02782533 - DBS of the Third Ventricle for Cluster Headache and Obesity N/A
Completed NCT04179266 - Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache Phase 1/Phase 2
Recruiting NCT04406259 - Atrioventricular Block and Cluster Headache (SEVA) Phase 4
Recruiting NCT06206772 - Resting State Functional Connectivity in Cluster Headache
Recruiting NCT03944876 - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Phase 3
Not yet recruiting NCT05857098 - Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
Recruiting NCT02910323 - The Will Erwin Headache Research Center - Cluster Headache Study
Terminated NCT00458770 - Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks N/A
Completed NCT00662935 - Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH) N/A
Active, not recruiting NCT03511846 - Pain Biomarker Study Phase 1
Completed NCT00184587 - Prophylactic Treatment of Episodic Cluster Headache Phase 2